Actinogen Medical - Funding in place through key catalysts
Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering...
187 Views
Actinogen Medical - First patient dosed in Phase IIb XanaMIA study
Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first...
192 Views
Actinogen Medical - Pressing forward with Xanamem
Having shown cognitive activity in prior trials, Actinogen began its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive...
238 Views
Actinogen Medical - Phase IIb XanaMIA study opens first study site
Actinogen Medical has opened the first investigational study site for its Phase IIb XanaMIA trial of lead candidate Xanamem in patients with...
613 Views
Actinogen Medical - Taking steps to mitigate funding headwinds
Actinogen is refining the design of its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated...
250 Views